Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.5 USD | +5.29% | +7.55% | -18.21% |
May. 07 | Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M | MT |
May. 07 | Transcript : Veracyte, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Chart calendar Veracyte, Inc.
Upcoming events on Veracyte, Inc.
Past events on Veracyte, Inc.
2024-05-07 04:30 pm | Q1 2024 Earnings Call |
2024-05-07 04:05 pm | Q1 2024 Earnings Release |
2024-05-06 12:10 pm | American Urological Association Meeting - Podium Presentation No PD57-11 |
2024-05-05 11:10 am | American Urological Association Meeting - Podium Presentation No PD42-05 |
2024-05-05 10:50 am | American Urological Association Meeting - Podium Presentation No PD42-03 |
2024-05-05 10:30 am | American Urological Association Meeting - Podium Presentation No PD42-01 |
2024-05-05 10:30 am | American Urological Association Meeting |
2024-05-05 08:00 am | American Urological Association Meeting - Poster No:MP49-09 |
2024-05-04 04:30 pm | American Urological Association Meeting - Poster No:MP41-09 |
2024-05-04 04:30 pm | American Urological Association Meeting - Poster No:MP41-13 |
2024-05-04 04:30 pm | American Urological Association Meeting - Poster No:MP41-14 |
2024-05-03 05:10 pm | American Urological Association Meeting |
2024-05-03 02:00 pm | American Urological Association Meeting - Poster No:MP15-02 |
2024-05-03 02:00 pm | American Urological Association Meeting - Poster No:MP15-07 |
2024-05-03 08:00 am | American Urological Association Meeting - Poster No:MP05-10 |
2024-03-04 09:50 am | Raymond James Institutional Investors Conference |
2024-02-22 04:30 pm | Q4 2023 Earnings Call |
2024-02-22 04:05 pm | Q4 2023 Earnings Release |
2024-01-08 04:30 pm | JPMorgan Healthcare Conference |
2023-12-01 01:45 pm | Society of Urologic Oncology Meeting - Poster No - #237 |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 120 120 0.13% | 117 116 1.49% | 220 215 2.27% | 297 291 1.79% | 361 355 1.71% | 405 |
EBITDA Million USD | Released Forecast Spread | -11,0 -6,99 -57.46% | -27,4 -26,9 -2.06% | -62,3 -63,1 1.19% | -15,2 -21,8 30.46% | -58,6 -22,5 -160.83% | 18,3 |
EBIT Million USD | Released Forecast Spread | -15,1 -11,2 -34.49% | -35,4 -33,0 -7.2% | -81,9 -79,4 -3.11% | -41,1 -47,0 12.67% | -85,8 -56,7 -51.25% | -11,7 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -12,6 -9,15 -37.7% | -34,9 -33,1 -5.33% | -81,6 -84,9 3.78% | -36,4 -43,2 15.77% | -76,6 -52,3 -46.49% | -5,16 |
Net income Million USD | Released Forecast Spread | -12,6 -9,07 -38.94% | -34,9 -33,0 -5.91% | -75,6 -79,0 4.3% | -36,6 -43,2 15.35% | -74,4 -52,9 -40.53% | -6,93 |
EPS USD | Released Forecast Spread | -0,27 -0,20 -35% | -0,66 -0,63 -4.1% | -1,11 -1,16 3.96% | -0,51 -0,60 15.28% | -1,02 -0,73 -40.05% | -0,10 |
Announcement Date | 25/02/20 | 17/02/21 | 28/02/22 | 22/02/23 | 22/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 67,8 61,9 9.48% | 72,9 68,1 7.02% | 75,6 66,4 13.83% | 80,3 74,9 7.18% | 82,4 75,7 8.81% | 90,3 83,1 8.71% | 90,1 84,4 6.78% | 98,2 92,8 5.85% | 96,8 93,4 3.74% | 99,6 | 101 | 107 | 106 | 111 |
EBITDA Million USD | Released Forecast Spread | -8,69 -15,3 43.13% | -4,24 -9,40 54.88% | -3,36 -10,6 68.34% | 1,14 -4,60 124.7% | -3,83 -0,30 -1176% | -1,19 -3,50 65.94% | -24,4 -1,30 -1778.15% | -29,2 3,00 -1072.37% | 7,80 | 8,70 | 11,2 | |||
EBIT Million USD | Released Forecast Spread | -15,2 -18,0 15.42% | -10,7 -16,0 32.84% | -9,68 -17,2 43.78% | -5,42 -10,7 49.19% | -10,5 -8,61 -21.91% | -8,05 -11,0 26.88% | -31,7 -10,3 -209.14% | -35,5 -5,98 -493.79% | -4,66 -10,7 56.46% | -2,22 | -1,17 | 2,25 | 1,38 | 4,13 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -14,5 -18,8 23.1% | -9,65 -15,6 38.2% | -8,88 -16,8 47.31% | -3,44 -10,3 66.45% | -8,09 -9,45 14.37% | -8,28 -11,0 24.56% | -29,8 -11,3 -163.26% | -30,5 -5,97 -410.66% | -1,91 -10,7 82.14% | -1,58 | -0,53 | 2,91 | 1,91 | 4,66 |
Net income Million USD | Released Forecast Spread | -14,5 -17,8 18.86% | -9,53 -16,3 41.6% | -8,72 -17,5 50.11% | -3,84 -10,4 63.12% | -8,09 -9,91 18.38% | -8,40 -11,2 25.28% | -29,6 -11,5 -158.63% | -28,3 -6,83 -314.28% | -1,86 -10,5 82.24% | -2,19 | -1,28 | 1,31 | 1,85 | 4,58 |
EPS USD | Released Forecast Spread | -0,20 -0,25 20% | -0,13 -0,23 43.97% | -0,12 -0,25 52.76% | -0,05 -0,14 65.28% | -0,11 -0,14 23.61% | -0,12 -0,16 23.41% | -0,41 -0,16 -164.52% | -0,39 -0,09 -317.87% | -0,02 -0,15 86.52% | -0,04 | -0,02 | 0,02 | -0,01 | 0,03 |
Announcement Date | 03/05/22 | 02/08/22 | 02/11/22 | 22/02/23 | 04/05/23 | 08/08/23 | 07/11/23 | 22/02/24 | 07/05/24 | - | - | - | - | - |
Past sector events for Veracyte, Inc.
2024-05-09 | SEEGENE, INC.: Q1 2024 Earnings Release |
2024-05-09 04:05 pm | GUARDANT HEALTH, INC.: Q1 2024 Earnings Release |
2024-05-09 04:01 pm | IOVANCE BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-08 04:05 pm | MARAVAI LIFESCIENCES HOLDINGS, INC.: Q1 2024 Earnings Release |
2024-05-08 04:05 pm | EXACT SCIENCES CORPORATION: Q1 2024 Earnings Release |
2024-05-07 04:05 pm | VERACYTE, INC.: Q1 2024 Earnings Release |
2024-04-26 | BGI GENOMICS CO., LTD.: Q1 2024 Earnings Release |
2024-04-12 | BGI GENOMICS CO., LTD.: Q4 2023 Earnings Release |
2024-02-28 04:05 pm | CAREDX, INC: Q4 2023 Earnings Release |
2024-02-28 04:01 pm | IOVANCE BIOTHERAPEUTICS, INC.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- VCYT Stock
- Calendar Veracyte, Inc.